Patient Name: _
DOB: ‘ _ l

UUID:CF12FC3E-41CA-48EE-AF88-15ACA2C0067D

 

, _
5 Accession 7 v. I

Surgical Pathology Report

I Fina!

TCGA-CS-AZLX-B1A-PR

ImmHIImlI"munInuIIImnunnnIIIII'I‘IiEII‘iiTﬁute“l
lllllllllllllllllllllIIIIIIIIIIIIIIIII lllllllllllllllll *1
||||llI|I||||||||||||||||IIIIIIIIIIIll ||ll|ll|||||||||||

SURGICAL PATHOLOGY REPORT
FINAL

 

Patient Name.- ,, us
Address Service:0bstetrics Accession !

» .
‘ocatio ‘ Taken
Gender: 2‘ ._ MRNﬁ Receivedw l
D03 ”7 Hospital kw Accessioned:'

Patient Type: Reportedﬁ "
Physician (s): [ﬂAv 0 ’3 go 7 /
M.D. \ all 0 3
a " Z c5317
Other Related Clinical Data: 3’71” CUM/"X , N05

DIAGNOSIS: ﬂ!
menus. canvtx, BIOPSY Z//”
— MODERATELY DIFFERENTIATED INVASIVE soumous CELL CARCINOMA

By this signature, I attest that the above diagnosis is

baséu upon my personal

examination of the slides(and/or other material indicated in the
diagnnqisn

‘ V , M.D.

‘**Report Electronically Reviewed and Signed Out By L
M.D."*
Microscopic Description and Comment:
Microscnnic examination substantiates the above cited diagnosis.

 

. »
History: A
The patient is {ear old woman with a last menses in _ )perative
procedure: Cervical biopsy.
Specimen(s) Received:
A: CERVIX
6
Gross Description
The specimen is received in one formalin-filled container labeled " _.
' and "cervical biopsy,." It holds multiple fragments of can tissue that range
from 0.2 to 0.4 cm. Lebeled R1 *c" 0.
LHE pertormance characteristics of some immunohistochemical stains, fluorescence
in~situ hybridization tests and immunophenotvoina bv F1nu FUPAMDFrU Pirpd in
this report (if any) were determined by the __ .
. as part of an ongoing quality assurance program and in
compliance With federally mandated regulations drawn from the Clinical
Laboratory Improvement Act of 1988 (CLIA '88). Some of these tests rely on the

 

Page 1 of 2

Patient Name:
DOB: an _ MRN.
. Accession: J'AN:

 

use of “analyte specific reagents“ and are subject to specific labeling
requirements by the US Food and Drug Administration. Such diagnostic tests may
only be performed in a facility that is certified by the Department of Health
and Human Services as a high complexity laboratory under CLIA '88. The FDA has
determined that such clearance or approval is not necessary. This test is used
for clinical purposes. It should not be regarded as investigational or for
research. Nevertheless, federal rules concerning the medical use of analyte
specific reagents require that the following disclaimer be attached to the
report:

This test was developed and its performance characteristics determined by
the . It has not been
cleared or approved by the U. S. Food and Drug Administration.

 

 

Page 2 of 2 Printed fron'

 

